Home › Research › Topics › memantine
memantine
271 studies tagged memantine, dated 1981-01-01 to 2026-10-14. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
271 studies carry this tag.
Date range
1981 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 15
- Neurology 11
- Journal of the American Geriatrics Society 9
- Research Square 8
- medRxiv 8
138 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
16/100
Of 22,025,599 individuals screened, 2,051,275 were eligible; matched cohorts ranged from 10,113 to 857,773, with median follow-up of 4.7 to 7.2 years.
-
The observed protective effect may be explained by vascular and neuroprotective mechanisms unique to PDE5 inhibitors.
-
These findings indicate that cognitive impairment may mark a population vulnerable to medication complexity rather than independently driving DDI risk, with polypharmacy emerging as the principal modifiable determinant.
-
In older adults with HFpEF, finerenone conferred renal benefit without a detectable short-term cognitive signal.
-
Rare confirmed initiation prevented a clinically interpretable admission-time strategy estimate.
-
Brexpiprazole was associated with a distinct neuropsychiatric adverse-event reporting pattern in Alzheimer’s disease compared with psychiatric indications, with the most consistent signals observed for delirium, falls, and agitation.
-
Medication adherence in older adults was strongly influenced by cognitive impairment, gender, health literacy and cohabitation.
-
Among 2,577,000 Veterans (mean age, 63 years; 4.5% female; 65% White; 15% Black), 10% initiated ARBs and 90% initiated ACEIs.
-
2.1 Case İnformation A 78 years old man was referred to the cardiology clinic because of mild dyspnea.
-
This case underscores the importance of routine sodium monitoring in elderly patients with dementia initiated on serotonergic or antipsychotic therapy.
-
Polypharmacy and PIMs are highly prevalent in end-of-life elderly cancer patients.
-
High placebo response is an obstacle in developing drugs to treat agitation in Alzheimer’s disease (AAD), a prevalent and burdensome symptom.
-
16/100
Late-onset unexplained epilepsy is a potential harbinger of dementia, likely driven by network hyperexcitability that facilitates amyloid-β release and tau propagation.
-
In propensity-matched comparator analyses, during the 2 year time-period from treatment initiation, semaglutide was associated with broadly lower neuropsychiatric event risk than metformin, SGLT2 inhibitors, and DPP-4 inhibitors.
-
BackgroundZervimesine (CT1812) is a first-in-class, brain-penetrant sigma-2 receptor ligand that prevents binding and displaces Aβ42 oligomers from receptors on neuronal synapses.
-
Mean percentage change in plasma p-tau217 in the SAMe group was an increase of 53.22 (standard deviation [SD] 159.19) compared to 25.34 (SD 94.83) in the placebo group (standardized mean difference 37.58, 95% confidence interval -32.61, 107.76; p = 0.288).
-
Both classes act on neuronal calcium signaling, raising the question of whether their combined use is associated with greater cognitive risk than gabapentin alone.
-
16/100
More than one-quarter of residents with ADRD remain untreated with guideline-recommended pharmacotherapy, and treatment varied significantly by non-clinical predictors.
-
Cardiovascular risk factors contribute to the majority of dementia cases, with about 20% directly attributable to vascular cognitive impairment and dementia (VCID).
-
The high incidence of new prescribing, as well as the lack of deprescribing, points to unmet needs and a role for more proactive medication review.
-
By addressing gaps in prior NMAs, this study aims to provide an in-depth evaluation of safety outcomes associated with different ChEI and memantine doses and formulations across various dementia types.
-
BackgroundPreclinical and clinical evidence suggest that low-dose cannabinoids could ameliorate Alzheimer's disease (AD) signs and symptoms.
-
Among 275,144 initiators of DPP-4 inhibitors or sulfonylureas, followed for 750,846 person-years, DPP-4 inhibitors were associated with a reduced dementia risk compared with sulfonylureas (4.4 vs. 5.7 events per 1000 person-years; HR 0.77, 95% CI 0.71-0.85).
-
Donepezil is a central-acting acetylcholinesterase inhibitor aimed at increasing acetylcholine availability at the neuron synapses to enhance cholinergic transmission.
-
A total of 210 participants were enrolled and 82% completed 26 weeks of treatment.
-
We found that 51.9% of DLB patients were ever prescribed a ChEI, and those who were prescribed a ChEI had a greater diagnosis interval.
-
Overall, 74 studies containing 92 cases were found of MDs related to ACHEIs.
-
The steady-state plasma PK results were closely aligned with the previous 2-week PK in the ALZ-801 phase 1b study in APOE4 carrier subjects with AD, as well as a phase 1 7-day PK study in heathy elderly volunteers.
-
Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson's disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements.
-
Blarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the individual 30 mg (by 34.6%) and 50 mg (by 38.5%) blarcamesine groups vs. placebo on the prespecified primary cognitive endpoint ADAS-Cog13.
-
Psychosis and agitation are among the most distressing neuropsychiatric symptoms (NPSs) of Alzheimer's disease (AD), linked to faster disease progression and earlier admission to nursing homes.
-
Alzheimer's disease (AD) affects millions of people worldwide.
-
75/100
There were 132 846 individuals (mean [SD] age, 80.4 [7.6] years; 61.8% women; mean [SD] body mass index [BMI], 25.5 [4.6]) with a diagnosis of dementia included in cohort 1, 159 419 individuals (mean [SD] age, 81.2 [7.6] years; 59.7% women; mean [SD] body mass index [BMI], 25.6 [4.7]) with a diagnosis of dementia included in cohort 2, and 92 328 individuals with a diagnosis of dementia included in cohort 3 (mean [SD] age, 80.9 [7.7] years; 58.5% women; mean [SD] body mass index [BMI], 25.5 [4.7]).
-
Seventeen RCTs, comprising 7214 participants, investigated the efficacy of the following drugs: Donepezil, Rivastigmine, Galantamine, Memantine, Ginkgo biloba extract (EGb), Atorvastatin-calcium and Vitamin B in the treatment of AD.
-
Alzheimer disease is a progressive, neurodegenerative disorder characterized by the accumulation of amyloid beta plaques and hyperphosphorylated tau proteins.
-
Overall, 12 489 patients initiating SGLT2 inhibitor treatment (51.9% dapagliflozin and 48.1% empagliflozin) and 1075 patients initiating dulaglutide treatment were included.
-
Each matched cohort included 23,386 (semaglutide vs sitagliptin), 22,584 (vs empagliflozin), and 19,206 (vs glipizide) patients.
-
The phase III program for Auvelity, showed that the drug was well tolerated with the most common side effects being dizziness, headache, and dry mouth. 86 Another novel antidepressant agent approved in 2023 is zuranolone (Zurzuvae).
-
All drugs improved the cognitive function, with the effect value ranging from -1.23 (95% CI -2.17 to -0.30) for 20 mg memantine to -3.29 (95% CI -4.14 to -2.45) for 32 mg galantamine.
-
The antidiabetic drugs include NE3107, an anti-inflammatory and insulin sensitizer, and the diabetes mainstream drug metformin.
-
Our TSMR analysis showed a significant positive association between genetic predisposition to methotrexate use and dementia risk.
-
No significant between-group effects of exenatide on ADAS-Cog11 score (p = 0.17) were detected.
-
The analysis included 8 randomized placebo-controlled trials with 6547 participants.
-
557 cases of TdP/QT prolongation related to 3 ChEIs were searched by SMQ.
-
Dementia is a debilitating neurological condition that is characterized by persistent cognitive decline.
-
Drug consumption went from 5,000 defined daily doses/1,000 inhabitants, in 2014, to more than 16,000/1,000 inhabitants, in 2020, and all federative units showed positive variation.
-
Out of 538 articles, 23 (4.27%) were published in journals from the geriatric category, 44 (8.18%) included an author affiliated with a geriatric institution.
-
RECENT FINDINGS: In a large autopsy series from a national consortium, multiple neuropathologies of dementia subtypes were common and increased severity of specific NPS during life was associated with greater severity of neuropathology across diagnoses.
-
Crude AD prevalence (2015-2020) was estimated at 760.5 per 100,000 inhabitants, and age-standardized prevalence (2020) was 664.6 (male 595.7, female 711.0).
-
Prevalence of dementia continues to increase with limited pharmacotherapy options available.
From across this tag
9 of the 271 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial
- Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients
- Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
- Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders
- Association between Statin Use and Sepsis Risk in Patients with Dementia: A Retrospective Cohort Study
- Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease in the Absence of Memantine1
- EGb 761® Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer's Dementia-Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial
- The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
- A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease